37.10

3.64% -1.47

Praxis Precision Medicines Inc (PRAX)

Overview News Price History Option Chain Financials Discussions Forecast

Praxis Precision Medicines Inc stock is traded at $37.10, with a volume of 113.98K. It is down -3.64% in the last 24 hours and down -57.11% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Previous Close:

$38.57

Open:

$38.47

24h Volume:

113.98K

Relative Volume:

0.27

Market Cap:

$759.05M

Revenue:

$1.77M

Net Income/Loss:

$-123.74M

P/E Ratio:

-4.0458

EPS:

-9.17

Net Cash Flow:

$-95.21M

1W Performance:

-1.86%

1M Performance:

-57.11%

6M Performance:

-37.93%

1Y Performance:

-32.66%

1-Day Range:

$36.55

$39.34

1-Week Range:

$34.91

$39.44

52-Week Range:

$33.01

$91.83

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name

Praxis Precision Medicines Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

617-300-8460

Address

99 HIGH STREET, 30TH FLOOR, BOSTON

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

PRAX's Discussions on Twitter

Compare PRAX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRAX Praxis Precision Medicines Inc	37.14	759.05M	1.77M	-123.74M	-95.21M	-9.17
VRTX Vertex Pharmaceuticals Inc	501.98	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	683.05	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	578.06	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.63	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	250.04	26.76B	3.32B	-860.46M	-1.04B	-8.32

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-03-25	Reiterated	H.C. Wainwright	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Aug-05-24	Initiated	Oppenheimer	Outperform
Jun-24-24	Initiated	Needham	Buy
Jun-18-24	Initiated	Guggenheim	Buy
May-01-24	Initiated	Robert W. Baird	Outperform
Sep-19-23	Initiated	Truist	Buy
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral
Dec-16-21	Initiated	H.C. Wainwright	Buy
Aug-26-21	Initiated	BofA Securities	Buy
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform
Nov-10-20	Initiated	Cowen	Outperform
Nov-10-20	Initiated	Evercore ISI	Outperform
Nov-10-20	Initiated	Piper Sandler	Overweight

View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

Mar 06, 2025

HC Wainwright Has Negative Estimate for PRAX Q1 Earnings - Defense World

Mar 06, 2025

Mar 05, 2025

Praxis Precision Medicines Updates on Programs and Finances - TipRanks

Mar 05, 2025

New York State Common Retirement Fund Boosts Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World

Mar 05, 2025

Rhumbline Advisers Cuts Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World

Mar 05, 2025

Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year Low Following Analyst Downgrade - Defense World

Mar 05, 2025

Mar 04, 2025

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Mar 04, 2025

Praxis Adds Six New Hires With $33.55 Stock OptionsWhat's Behind This Talent Acquisition? - StockTitan

Mar 04, 2025

Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences - GlobeNewswire

Mar 04, 2025

Praxis Precision price target lowered to $85 from $150 at Needham - Yahoo Finance

Mar 04, 2025

CNS Therapy Developer PRAX Lines Up Five Major Investor ConferencesWhat's Their 2025 Strategy? - StockTitan

Mar 04, 2025

Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide (NASDAQ:PRAX) - Seeking Alpha

Mar 04, 2025

Praxis Precision Medicines (NASDAQ:PRAX) Given New $105.00 Price Target at HC Wainwright - Defense World

Mar 04, 2025

Praxis Precision Medicines (NASDAQ:PRAX) Price Target Cut to $85.00 by Analysts at Needham & Company LLC - Defense World

Mar 04, 2025

Praxis Precision Medicines (NASDAQ:PRAX) Given New $73.00 Price Target at Robert W. Baird - Defense World

Mar 04, 2025

Praxis Precision Medicines (NASDAQ:PRAX) Price Target Lowered to $85.00 at Truist Financial - Defense World

Mar 04, 2025

Mar 03, 2025

Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade) - Seeking Alpha

Mar 03, 2025

Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate - Benzinga India

Mar 03, 2025

Praxis Precision (PRAX) Stock Price Target Cut By Half - AskTraders

Mar 03, 2025

Praxis Precision price target lowered to $85 from $175 at Truist - TipRanks

Mar 03, 2025

Praxis Precision Medicines Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 03, 2025

Praxis Precision tanks on negative ulixacaltamide news - The Pharma Letter

Mar 03, 2025

Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $65 From $111, Maintains Buy Rating - Marketscreener.com

Mar 03, 2025

Assessing Praxis Precision Medicine: Insights From 5 Financial Analysts - Benzinga

Mar 03, 2025

Praxis Precision Medicines: A Compelling Buy Amidst Promising Pipeline Developments - TipRanks

Mar 03, 2025

Mar 02, 2025

Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down After Earnings Miss - Defense World

Mar 02, 2025

Mar 01, 2025

Praxis Precision Medicines (PRAX) Projected to Post Quarterly Earnings on Friday - MarketBeat

Mar 01, 2025

Feb 28, 2025

Praxis cites doubts over late-stage trial success: Wedbush downgrades (update) - MSN

Feb 28, 2025

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update - GlobeNewswire

Feb 28, 2025

Praxis to advance late-stage program for lead asset despite doubts over success - MSN

Feb 28, 2025

Praxis stock price target cut to $61 at TD Cowen By Investing.com - Investing.com Australia

Feb 28, 2025

Items Tagged with 'relutrigine' - BioWorld Online

Feb 28, 2025

Items Tagged with 'vormatrigine' - BioWorld Online

Feb 28, 2025

Praxis Aims To Complete ET Trial Despite Likely Primary Endpoint Miss - Citeline News & Insights

Feb 28, 2025

Praxis stock price target cut to $61 at TD Cowen - Investing.com India

Feb 28, 2025

Wedbush Downgrades Praxis Precision Medicines to Underperform From Neutral, Cuts Price Target to $26 From $57; Shares Fall - Marketscreener.com

Feb 28, 2025

Market Whales and Their Recent Bets on PRAX Options - Benzinga

Feb 28, 2025

H.C. Wainwright sees opportunity for quick rebound from Praxis after setback - TipRanks

Feb 28, 2025

Truist cuts Praxis stock target to $85, maintains buy rating By Investing.com - Investing.com South Africa

Feb 28, 2025

Truist cuts Praxis stock target to $85, maintains buy rating - Investing.com

Feb 28, 2025

Praxis Precision Medicines: Navigating Challenges and Catalysts in Epilepsy Treatment - TipRanks

Feb 28, 2025

Buy Rating Maintained for Praxis Precision Medicines Despite Essential3 Setback, Focus on Promising Pipeline and Strong Financial Position - TipRanks

Feb 28, 2025

Truist Securities Adjusts Praxis Precision Medicines Price Target to $85 From $175, Maintains Buy Rating; Shares Plunge - Marketscreener.com

Feb 28, 2025

Recursion Pharmaceuticals, DoubleVerify Holdings, Praxis Precision Medicines - TradingView

Feb 28, 2025